Inventor · disambiguated record

Jean-François Dubuisson

Also filed as: DUBUISSON JEAN · DUBUISSON JEAN-FRANCOIS · DUBUISSON JEAN-FRANÇOIS

41 granted patents·13 pending applications·705 citations·filing 2002–2025

98Inventor score

Technology areasA61K A61P C07K G01N C12N

Files withFLAMEL IRELAND LTD44 CENTRE NAT RECH SCIENT3 INST NAT SANTE RECH MED3 INSERM INSTITUT NAT DE LA SANTE ET DE LA RECHERCH MEDICALE1 INSERM INSTITUT NATIONAL DE LA SANTEET DE LA RECH MEDICALE1

Top patents by PatentIndex Score

54 records

0199US11839597B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2021·Granted Dec 12, 2023·27 cites·30 claims
0299US11065224B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2019·Granted Jul 20, 2021·42 cites·38 claims
0399US10973795B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2019·Granted Apr 13, 2021·48 cites·24 claims
0499US10952986B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2019·Granted Mar 23, 2021·50 cites·31 claims
0598US11052061B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2019·Granted Jul 6, 2021·33 cites·24 claims
0698US11000498B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2019·Granted May 11, 2021·38 cites·20 claims
0797US12128021B1Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2024·Granted Oct 29, 2024·12 cites·26 claims
0897US12097175B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2023·Granted Sep 24, 2024·9 cites·30 claims
0997US11986451B1Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2021·Granted May 21, 2024·24 cites·26 claims
1097US11504347B1Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2021·Granted Nov 22, 2022·38 cites·25 claims
1197US10736866B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2019·Granted Aug 11, 2020·53 cites·52 claims
1297US10272062B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2017·Granted Apr 30, 2019·68 cites·89 claims
1396US12257223B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2024·Granted Mar 25, 2025·2 cites·14 claims
1496US12138239B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2023·Granted Nov 12, 2024·9 cites·30 claims
1596US12115145B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2023·Granted Oct 15, 2024·10 cites·29 claims
1696US12115144B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2023·Granted Oct 15, 2024·10 cites·15 claims
1796US12115143B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2023·Granted Oct 15, 2024·10 cites·26 claims
1896US12115142B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2023·Granted Oct 15, 2024·10 cites·30 claims
1996US11896572B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2023·Granted Feb 13, 2024·28 cites·1 claims
2096US11826335B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2023·Granted Nov 28, 2023·27 cites·10 claims
2196US11766418B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2022·Granted Sep 26, 2023·27 cites·11 claims
2296US11602512B1Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2021·Granted Mar 14, 2023·36 cites·11 claims
2396US11602513B1Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2021·Granted Mar 14, 2023·36 cites·27 claims
2496US11583510B1Methods of administering gamma hydroxybutyrate formulations after a high-fat mealFLAMEL IRELAND LTD·Filed 2022·Granted Feb 21, 2023·37 cites·14 claims
2595US12226388B2Modified release gamma- hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2024·Granted Feb 18, 2025·2 cites·29 claims
2695US11779557B1Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2022·Granted Oct 10, 2023·7 cites·6 claims
2794US12263150B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2024·Granted Apr 1, 2025·1 cites·19 claims
2894US12263151B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2024·Granted Apr 1, 2025·1 cites·15 claims
2994US12239625B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2024·Granted Mar 4, 2025·1 cites·15 claims
3094US12226389B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2024·Granted Feb 18, 2025·1 cites·14 claims
3194US12186298B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2024·Granted Jan 7, 2025·1 cites·26 claims
3294US12109186B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2023·Granted Oct 8, 2024·1 cites·11 claims
3393US12186296B1Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2021·Granted Jan 7, 2025·2 cites·63 claims
3489US12144793B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2023·Granted Nov 19, 2024·0 cites·23 claims
3589US12097176B2Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2023·Granted Sep 24, 2024·0 cites·6 claims
3689US2024366548A1Modified release gamma- hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2024·Application pending·0 cites
3784US2025099417A1Modified release gamma- hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2024·Application pending·0 cites
3880US2022016066A1Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2021·Application pending·0 cites
3980US2025205187A1Modified release gamma- hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2025·Application pending·0 cites
4079US2021267928A1Modified release gamma- hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2021·Application pending·0 cites
4178US2023210804A1Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2023·Application pending·0 cites
4274US12478604B1Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2022·Granted Nov 25, 2025·0 cites·15 claims
4372US12295926B1Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsFLAMEL IRELAND LTD·Filed 2022·Granted May 13, 2025·0 cites·7 claims
4470US11141440B2Pharmaceutical oral formulation comprising bacteriaMAAT PHARMA·Filed 2018·Granted Oct 12, 2021·1 cites·20 claims
4567US7314710B2Method for replicating the hepatitis C virusCENTRE NAT RECH SCIENT·Filed 2002·Granted Jan 1, 2008·2 cites·5 claims
4665US10875896B2Hepatitis E virus ORF2 capsid polypeptides and uses thereofINSERM INSTITUT NATIONAL DE LA SANTEET DE LA RECH MEDICALE·Filed 2018·Granted Dec 29, 2020·1 cites·5 claims
4764US2023340030A1Hepatitis e virus orf2 capsid polypeptides and uses thereofINST NAT SANTE RECH MED·Filed 2023·Application pending·0 cites
4855US2010159467A1Method for replicating the hepatitis c virusCENTRE NAT RECH SCIENT·Filed 2009·Application pending·0 cites
4954US2021179669A1Hepatitis e virus orf2 capsid polypeptides and uses thereofINST NAT SANTE RECH MED·Filed 2020·Application pending·0 cites
5052US7655406B2Nucleotide sequences coding for the non-structural proteins of the hepatitis C virusCENTRE NAT RECH SCIENT·Filed 2007·Granted Feb 2, 2010·0 cites·4 claims

Showing the top 50 of 54 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Jean-François Dubuisson files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →